Daniel Vaena, MD, discusses the treatment of patients with metastatic castration-naïve disease and nonmetastatic castration-resistant prostate cancer, underscoring the importance of risk stratification in both settings.
Original Article: Assessing Risk Stratification Across Pivotal Prostate Cancer Trials
NEXT ARTICLE